944256-13-7

Basic information

• Product Name: [(R)-4-amino-4-(3,4-dimethoxyphenyl)butyl]carbamic acid tert-butyl ester
• Synonyms: [(R)-4-amino-4-(3,4-dimethoxyphenyl)butyl]carbamic acid tert-butyl ester
• CAS NO: 944256-13-7
• Molecular Weight: 324.42
• Mol File: 944256-13-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [(R)-4-amino-4-(3,4-dimethoxyphenyl)butyl]carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(R)-4-amino-4-(3,4-dimethoxyphenyl)butyl]carbamic acid tert-butyl ester(944256-13-7)
• EPA Substance Registry System: [(R)-4-amino-4-(3,4-dimethoxyphenyl)butyl]carbamic acid tert-butyl ester(944256-13-7)

Safety Data

• Hazardous Substances Data: 944256-13-7(Hazardous Substances Data)

Upstream product

• 944256-12-6 [4-(3,4-dimethoxyphenyl)-4-(R)-(2,2,2-trifluoroacetylamino)butyl]carbamic acid tert-butyl ester 

Downstream Products

• 944256-14-8 C₂₅H₃₀N₂O₇ 
• 1190089-54-3 C₂₅H₃₁BrN₂O₅ 

Relevant articles and documents

Nonpeptide urotensin-II receptor antagonists: A new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits

We have discovered two related chemical series of nonpeptide urotensin-II (U-II) receptor antagonists based on piperazino-phthalimide (5 and 6) and piperazino-isoindolinone (7) scaffolds. These structure types are distinctive from those of U-II receptor antagonist series reported in the literature. Antagonist 7a exhibited single-digit nanomolar potency in rat and human cell-based functional assays, as well as strong binding to the human U-II receptor. In advanced pharmacological testing, 7a blocked the effects of U-II in vitro in a rat aortic ring assay and in vivo in a rat ear-flushmodel. Adiscussion of U-II receptor antagonist pharmacophores is presented, and a specifically defined model is suggested from tricycle 13, which has a high degree of conformational constraint.

UROTENSIN II RECEPTOR ANTAGONISTS

The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.